TY - JOUR
T1 - Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests
AU - Boursier, J
AU - Roux, Marine
AU - Costentin, Charlotte
AU - Chaigneau, Julien
AU - Fournier-Poizat, Céline
AU - Trylesinski, Aldo
AU - Canivet, CM
AU - Michalak, Sophie
AU - Le, Bail B
AU - Paradis, Valérie
AU - Bedossa, Pierre
AU - Sturm, Nathalie
AU - de, Ledinghen V
AU - Barthelon, Justine
AU - Boursier, J
AU - Cales, Paul
AU - Canivet, C
AU - Decaens, Thomas
AU - Delamarre, Adèle
AU - Hermabessiere, Paul
AU - Irles-Depé, Marie
AU - de, Ledinghen V
AU - Hilleret, Marie Noelle
AU - Fouchard-Hubert, Isabelle
AU - Lannes, Adrien
AU - Le, Bail B
AU - Moal, Valérie
AU - Oberti, Fréderic
AU - Allison, Michael
AU - Anstee, Quentin M.
AU - Cobbold, Jeremy F.
AU - Deeks, Jonathan J.
AU - Eddowes, Peter J.
AU - Guha, Indra N.
AU - Sheridan, David
AU - Tsochatzis, Emmanuel
AU - Newsome, Philip N.
PY - 2023/8/26
Y1 - 2023/8/26
N2 - Unlike for advanced liver fibrosis, the practical rules for the early non-invasive diagnosis of cirrhosis in NAFLD remain not well defined. Here, we report the derivation and validation of a stepwise diagnostic algorithm in 1568 patients with NAFLD and liver biopsy coming from four independent cohorts. The study algorithm, using first the elastography-based tests Agile3+ and Agile4 and then the specialized blood tests FibroMeterV3G and CirrhoMeterV3G, provides stratification in four groups, the last of which is enriched in cirrhosis (71% prevalence in the validation set). A risk prediction chart is also derived to allow estimation of the individual probability of cirrhosis. The predicted risk shows excellent calibration in the validation set, and mean difference with perfect prediction is only −2.9%. These tools improve the personalized non-invasive diagnosis of cirrhosis in NAFLD.
AB - Unlike for advanced liver fibrosis, the practical rules for the early non-invasive diagnosis of cirrhosis in NAFLD remain not well defined. Here, we report the derivation and validation of a stepwise diagnostic algorithm in 1568 patients with NAFLD and liver biopsy coming from four independent cohorts. The study algorithm, using first the elastography-based tests Agile3+ and Agile4 and then the specialized blood tests FibroMeterV3G and CirrhoMeterV3G, provides stratification in four groups, the last of which is enriched in cirrhosis (71% prevalence in the validation set). A risk prediction chart is also derived to allow estimation of the individual probability of cirrhosis. The predicted risk shows excellent calibration in the validation set, and mean difference with perfect prediction is only −2.9%. These tools improve the personalized non-invasive diagnosis of cirrhosis in NAFLD.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1353/viewcontent/Practical_20diagnosis_20of_20cirrhosis_20in_20non_alcoholic_20fatty_20liver_20disease_20using_20currently_20available_20non_invasive_20fibrosis_20tests.pdf
U2 - 10.1038/s41467-023-40328-4
DO - 10.1038/s41467-023-40328-4
M3 - Article
SN - 2041-1723
VL - 14
JO - Nature Communications
JF - Nature Communications
IS - 1
ER -